The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)

Podobne zapisy

• Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide
  od: Göhring, Gudrun, i wsp.
  Wydane: (2011)
• Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses
  od: Giagounidis, Aristoteles A. N., i wsp.
  Wydane: (2006)
• Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)
  od: Sekeres, M A, i wsp.
  Wydane: (2014)
• Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study
  od: Giagounidis, Aristoteles, i wsp.
  Wydane: (2014)
• Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes
  od: Giagounidis, Aristoteles, i wsp.
  Wydane: (2013)